Vnitřní lékařství 1/2020

PŘEHLEDOVÉ ČLÁNKY Dvacet let cesty nefrologa do hlubin toxicity fosforu | 25  / Vnitř Lék 2020; 66(E-1): 19–25 /  VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 14. Týcová I, Sulková SD, Štěpánková J, et al. Molecular patterns of diffuse and nodular parathyroid hyperplasia in long-term hemodialysis. Am J Physiol Endocrinol Metab 2016; 311: E720–E729. 15. Silver J, Kilav R, Naveh-Many T Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2002; 283: F367–F376. 16. Komaba H, Fukagawa M Phosphate-a poison for humans? Kidney Int 2016; 90: 753–763. 17. Vanholder R, Argiles A, Baurmeister U, et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001; 24: 695–725. 18. Hyšpler R, Tichá A, Šafránek R, et al. Indoxyl Sulfate Elimination in Renal Replacement Therapy: Influence of Citrate- versus Acetate-Buffering Component during Bicarbonate Dialysis. Dis Markers 2018; 15: 3985–3986. 19. Ritter CS, Slatopolsky E Phosphate Toxicity in CKD: The Killer among Us. Clin J Am Soc Nephrol 2016; 11: 1088–1100. 20. Moe SM Calcium as a cardiovascular toxin in CKD-MBD. Bone 2017; 100: 94–99. 21. Lynch K, Lynch R, Curhan GC, et al. Prescribed dietary phosphate restriction and survi- val among hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 620–629. 22. Sekercioglu N, Thabane L, Diaz-Martinez JP, et al. Comparative Effectiveness of Phos- phate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. PLoS One 2016; 11(6): e0156891. 23. Floege J. Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol 2016; 29: 329–340. 24. Isakova T, Ix JH, Sprague SM, et al. Rationale and Approaches to Phosphate and Fibrob- last Growth Factor 23 Reduction in CKD. J Am Soc Nephrol 2015; 26: 2328–2339. 25. Mehta R, Isakova T Continued search for therapies to favourably modify phosphate and FGF-23 levels in CKD. Clin J Am Soc Nephrol 2017; 12: 1911–1913. 26. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chro- nic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s chan- ged and why it matters. Kidney Int 2017; 92: 26–36. 27. Cozzolino M. CKD-MBD KDIGO guidelines: how difficult is reaching the “target”? Clin Kidney J 2018; 11: 70–72. 28. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, preventi- on, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kid- ney Int Suppl 2017; 7: 1–59. 29. Lopot F, Švára F, Polakovič . „Revival domácí dialýzy”. Aktuality v nefrologii 2018; 24: 46–55. 30. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945–1953. 31. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and tre- atment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76: (Suppl. 113): S3–S130. 32. Brunerová L, Palicka V, Sulkova SD. Commentary on management of osteoporosis in advanced CKD: common view of a nephrologist and a bone specialist. Endocr Pract 2019; 25: 193–196. 33. Lau WL, Pai A, Moe SM, et al. Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis 2011; 18: 105–112. 34. Cozzolino M, Ciceri P, Galassi A. The Key Role of Phosphate on Vascular Calcification. Toxins 2019; 11: 213. 35. Disthabanchong S. Phosphate and cardiovascular disease beyond chronic kidney di- sease and vascular calcification. Int J Nephrology 2018; doi.org/10.1155/2018/3152806 36. Razzaque MS The FGF23-Klotho axis: endocrine regulation of phosphate homeosta- sis. Nat Rev Endocrinol 2009; 5: 611–619. 37. Grabner A, Mazzaferro S, Cianciolo G. Fibroblast Growth Factor 23: Mineral Metaboli- sm and Beyond. Contrib Nephrol 2017; 190: 83–95. 38. RodriguezM,LorenzoV. Parathyroidhormone,a uremictoxin.SeminDial2009;22:363–368. 39. Navarro-García JA, Fernández-Velasco M, Delgado C, et al. PTH, vitamin D, and the FGF-23-klotho axis and heart: Going beyond the confines of nephrology. Eur J Clin Invest 2018; 48: doi: 10.1111/eci.12902. 40. Gutiérrez OM, Mannstadt M, Isakova T. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584–592. 41. Agarwal I, Ide N, Ix JH. Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc 2014; 3: e000584. 42. Ho LY, Wong PN, Sin HK, et al. Risk factors and clinical course of hungry bone syn- drome after total parathyroidectomy in dialysis patients with secondary hyperparathy- roidism. BMC Nephrol 2017; 18: 12. 43. Wang J, Zhou JJ, Robertson GR, et al. Vitamin D in Vascular Calcification: A Double-Ed- ged Sword? Nutrients 2018; 10. pii: E652. 44. NigwekarSU,ThadhaniR,BrandenburgVM.Calciphylaxis.NEnglJMed2018;378:1704–1714. 45. Nigwekar SU, Kroshinsky D, Nazarian RM. Calciphylaxis: risk factors, diagnosis, and tre- atment. Am J Kidney Dis 2015; 66: 133–146. Víte, že listovačky časopisu Klinická farmakologie a farmacie jsou volně dostupné on-line? Mohou být přínosné i pro vás… V posledních číslech najdete tato hlavní témata: Farmakoterapie v anesteziologii (2/2019) Oftalmologie (1/2019) Pneumologie (4/2018) Gastroenterologie (3/2018) Nefrologie (1/2018) ... a mnoho článků z jiných oblastí medicíny a farmacie www. klinickafarmakologie.cz